Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MedAdvisor Limited ( (AU:MDR) ) just unveiled an announcement.
MedAdvisor Limited reported a significant decline in its financial performance for FY25, with revenue from continuing operations dropping by 36% due to underperformance in US health programs. The company has sold its ANZ business division to Jonas Software AUS, aiming to focus on strengthening its US operations through cost reductions and platform development. Despite a challenging year, MedAdvisor is committed to maximizing shareholder value by restructuring its US commercial operations and continuing its Transformation 360° initiative.
The most recent analyst rating on (AU:MDR) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on MedAdvisor Limited stock, see the AU:MDR Stock Forecast page.
More about MedAdvisor Limited
MedAdvisor Limited is a leader in pharmacy-driven patient engagement solutions, focusing on enhancing interactions between pharmacies and patients.
Average Trading Volume: 955,572
Technical Sentiment Signal: Sell
Current Market Cap: A$34.39M
Find detailed analytics on MDR stock on TipRanks’ Stock Analysis page.